Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11206MR)

This product GTTS-WQ11206MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF18 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_004195.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8784
UniProt ID Q9Y5U5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11206MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4321MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIVV009
GTTS-WQ593MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ1398MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ2338MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ236MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ14293MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7221
GTTS-WQ12138MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ11485MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MetMAb
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW